Cookies on the Economic Times website

Economic Times has updated its Privacy and Cookie policy. We use cookies to ensure that we give you the better experience on our website. If you continue without changing your settings,we'll assume that you are happy to receive all cookies on the Economic Times website. However, you can change your cookie setting at any time by clicking on our Cookie Settings at any time.You can also see our Privacy Policy

View: India’s pharma industry needs innovation-promoting and smart regulation to up its game


Reform of regulation and of the review process pertaining to new drug development can go a long way in encouraging and sustaining research in new drug discovery.


The Indian pharmaceutical industry is a fine example of how such investment in R&D, combined with supportive public policy, has created global players. However, the pharma, biology and healthcare industry needs a public policy framework that will support private investment in R&D and innovation to maintain India’s pre-eminent position in this sector.

By Habil KhorakiwalaThe ongoing Covid-19 pandemic and the global race to develop a reliable vaccine, with attendant concerns about ‘vaccine nationalism’, reinforce the importance of investing in domestic research and development (R&D). Prime Minister Narendra Modi recognised the strategic importance of promoting indigenous innovation and entrepreneurship when he set up the Atal Innovation Mission (AIM).The cornerstone of an Atmanirbhar

To Read the Full Story, Become an ET Prime Member

Access the exclusive Economic Times stories, Editorial and Expert opinion


  • Sharp Insight-rich, Indepth stories across 20+ sectors

  • Access the exclusive Economic Times stories, Editorial and Expert opinion

  • Clean experience with
    Minimal Ads
  • Comment & Engage with ET Prime community
  • Exclusive invites to Virtual Events with Industry Leaders
  • A trusted team of Journalists & Analysts who can best filter signal from noise